Trial Profile
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Apr 2020
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 05 Jun 2018 Status changed to discontinued due to slow accrual; no formal hypothesis testing was performed as per results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 31 Jul 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov.